AU741215B2 - Sulfonylurea-glitazone synergistic combinations for diabetes - Google Patents
Sulfonylurea-glitazone synergistic combinations for diabetes Download PDFInfo
- Publication number
- AU741215B2 AU741215B2 AU55908/98A AU5590898A AU741215B2 AU 741215 B2 AU741215 B2 AU 741215B2 AU 55908/98 A AU55908/98 A AU 55908/98A AU 5590898 A AU5590898 A AU 5590898A AU 741215 B2 AU741215 B2 AU 741215B2
- Authority
- AU
- Australia
- Prior art keywords
- glyburide
- baseline
- patients
- troglitazone
- sulfonylurea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010012601 diabetes mellitus Diseases 0.000 title description 24
- 239000011885 synergistic combination Substances 0.000 title description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 133
- 229960004580 glibenclamide Drugs 0.000 claims description 123
- 238000011282 treatment Methods 0.000 claims description 87
- 229940100389 Sulfonylurea Drugs 0.000 claims description 70
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 63
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 55
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 32
- 239000003472 antidiabetic agent Substances 0.000 claims description 22
- 229960004586 rosiglitazone Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 229940125708 antidiabetic agent Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 230000002195 synergetic effect Effects 0.000 claims description 12
- 229960001764 glibornuride Drugs 0.000 claims description 6
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims description 6
- 229960001381 glipizide Drugs 0.000 claims description 6
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 6
- 229960003236 glisoxepide Drugs 0.000 claims description 6
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 5
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001761 chlorpropamide Drugs 0.000 claims description 5
- 229960002277 tolazamide Drugs 0.000 claims description 5
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 5
- 229960005371 tolbutamide Drugs 0.000 claims description 5
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 4
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001466 acetohexamide Drugs 0.000 claims description 4
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000346 gliclazide Drugs 0.000 claims description 4
- 229960003468 gliquidone Drugs 0.000 claims description 4
- RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 claims description 4
- 229950005514 glycyclamide Drugs 0.000 claims description 4
- -1 phenbentamide Chemical compound 0.000 claims description 4
- AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 claims description 3
- 229950008557 phenbutamide Drugs 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 claims 3
- NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 claims 3
- 229950008290 glyhexamide Drugs 0.000 claims 3
- 239000003643 water by type Substances 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 description 127
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 127
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 127
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 94
- 238000009097 single-agent therapy Methods 0.000 description 93
- 230000008859 change Effects 0.000 description 72
- 238000002648 combination therapy Methods 0.000 description 62
- 102000004877 Insulin Human genes 0.000 description 47
- 108090001061 Insulin Proteins 0.000 description 47
- 229940125396 insulin Drugs 0.000 description 47
- 230000002641 glycemic effect Effects 0.000 description 41
- 238000004458 analytical method Methods 0.000 description 30
- 230000007423 decrease Effects 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 26
- 150000002632 lipids Chemical class 0.000 description 23
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 22
- 108010075254 C-Peptide Proteins 0.000 description 22
- 230000009467 reduction Effects 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical class C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 19
- 230000006872 improvement Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 206010022489 Insulin Resistance Diseases 0.000 description 17
- 230000002411 adverse Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 108010010234 HDL Lipoproteins Proteins 0.000 description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000002483 medication Methods 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 9
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000021588 free fatty acids Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000003178 anti-diabetic effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- 206010014486 Elevated triglycerides Diseases 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 229940120105 glynase Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 229940084921 micronized glyburide Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229950002375 englitazone Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 108010036110 hemoglobin AC Proteins 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000011545 laboratory measurement Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229940102112 troglitazone 200 mg Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LAGDFTWBWDBEHD-UHFFFAOYSA-N 2,4,5,6-tetramethyl-1h-benzimidazole Chemical compound CC1=C(C)C=C2NC(C)=NC2=C1C LAGDFTWBWDBEHD-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- YSDKVGBRGBPNGH-UHFFFAOYSA-N CN1C(C=C(C=C2)OC)=C2N=C1COC1=CC=C(CC2SCCN2)C=C1 Chemical compound CN1C(C=C(C=C2)OC)=C2N=C1COC1=CC=C(CC2SCCN2)C=C1 YSDKVGBRGBPNGH-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 239000009261 D 400 Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010051083 Therapy responder Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005533 aryl carboxamido group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940102106 troglitazone 300 mg Drugs 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3822497P | 1997-02-19 | 1997-02-19 | |
| US60/038224 | 1997-02-19 | ||
| PCT/US1997/021996 WO1998036755A1 (en) | 1997-02-19 | 1997-12-01 | Sulfonylurea-glitazone synergistic combinations for diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5590898A AU5590898A (en) | 1998-09-09 |
| AU741215B2 true AU741215B2 (en) | 2001-11-29 |
Family
ID=21898725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU55908/98A Ceased AU741215B2 (en) | 1997-02-19 | 1997-12-01 | Sulfonylurea-glitazone synergistic combinations for diabetes |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US5859037A (enExample) |
| EP (1) | EP0957923A1 (enExample) |
| JP (1) | JP2001512478A (enExample) |
| KR (1) | KR20000071179A (enExample) |
| CN (1) | CN1244801A (enExample) |
| AR (1) | AR011829A1 (enExample) |
| AU (1) | AU741215B2 (enExample) |
| BG (1) | BG103671A (enExample) |
| BR (1) | BR9714505A (enExample) |
| CA (1) | CA2272478A1 (enExample) |
| CZ (1) | CZ289299A3 (enExample) |
| EA (1) | EA199900725A1 (enExample) |
| EE (1) | EE9900345A (enExample) |
| GT (1) | GT199800037A (enExample) |
| HN (1) | HN1997000167A (enExample) |
| HU (1) | HUP0001528A3 (enExample) |
| IL (1) | IL130027A (enExample) |
| IS (1) | IS5058A (enExample) |
| NO (1) | NO993982L (enExample) |
| NZ (1) | NZ336002A (enExample) |
| PA (1) | PA8447401A1 (enExample) |
| PE (1) | PE74399A1 (enExample) |
| PL (1) | PL335166A1 (enExample) |
| SK (1) | SK111899A3 (enExample) |
| SV (1) | SV1998000010A (enExample) |
| TR (1) | TR199902033T2 (enExample) |
| UY (1) | UY24893A1 (enExample) |
| WO (1) | WO1998036755A1 (enExample) |
| ZA (1) | ZA981343B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| EP1787646A3 (en) * | 1997-06-18 | 2007-10-03 | Smithkline Beecham Plc | Novel method of treatment |
| US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| KR20010013840A (ko) * | 1997-06-18 | 2001-02-26 | 피터 기딩스 | 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료 |
| GB9715306D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US7105552B2 (en) | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| GB9824893D0 (en) * | 1998-11-12 | 1999-01-06 | Smithkline Beckman Corp | Novel method of treatment |
| CA2354053A1 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| US7001746B1 (en) * | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
| CA2367955C (en) * | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US20060154864A1 (en) * | 1999-11-01 | 2006-07-13 | Emory University | Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same |
| US7563775B2 (en) * | 2000-11-01 | 2009-07-21 | Betty C. Villafuerte | Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes |
| FR2802814B1 (fr) * | 1999-12-23 | 2002-02-22 | Aventis Pharma Sa | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees |
| TR200401145T4 (tr) | 2000-04-13 | 2004-07-21 | Pfizer Products Inc. | Gliburit ve milrinonun sinerjistik etkisi. |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
| US6492339B1 (en) | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
| SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| CN100544717C (zh) | 2002-09-20 | 2009-09-30 | 华生制药公司 | 含有双胍和噻唑烷二酮衍生物的药物剂型 |
| US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US20040147564A1 (en) * | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
| ES2556244T3 (es) | 2003-10-31 | 2016-01-14 | Takeda Pharmaceutical Company Limited | Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán |
| MXPA04009236A (es) * | 2004-09-23 | 2006-03-27 | Jorge Luis Rosado Loria | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
| US20060188590A1 (en) * | 2005-01-05 | 2006-08-24 | Mitsunori Ono | Compositions for treating diabetes or obesity |
| US20090227493A1 (en) * | 2005-05-27 | 2009-09-10 | Daiichi Sankyo Company, Limited | Combined drug for treating diabetes |
| US20090286722A1 (en) * | 2005-09-08 | 2009-11-19 | Utech Limited | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function |
| US20090170762A1 (en) * | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
| US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| MXPA05013220A (es) * | 2005-12-06 | 2007-06-05 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. |
| JP5179363B2 (ja) | 2005-12-22 | 2013-04-10 | 武田薬品工業株式会社 | 固形製剤 |
| WO2008026668A1 (en) * | 2006-08-31 | 2008-03-06 | Daiichi Sankyo Company, Limited | Medicinal composition containing insulin resistance improving agent |
| KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| PL2868315T3 (pl) | 2007-12-04 | 2018-06-29 | Biogen Chesapeake Llc | Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty |
| FR2928836B1 (fr) * | 2008-03-21 | 2011-08-26 | Servier Lab | Forme galenique secable permettant une liberation modifiee du principe actif |
| CN107320732B (zh) * | 2008-12-04 | 2021-09-07 | 于崇曦 | 高穿透性组合物及其应用 |
| US20110065756A1 (en) * | 2009-09-17 | 2011-03-17 | De Taeye Bart M | Methods and compositions for treatment of obesity-related diseases |
| ES2525748T3 (es) * | 2009-11-13 | 2014-12-29 | Toray Industries, Inc. | Agente terapéutico o profiláctico para la diabetes |
| US9241952B2 (en) | 2010-05-24 | 2016-01-26 | Ozstar Therapeutics Pty Ltd | Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin |
| KR102584819B1 (ko) | 2011-01-19 | 2023-10-05 | 프랙틸 헬쓰, 인코포레이티드 | 조직의 치료를 위한 장치 및 방법 |
| AU2012343332B2 (en) | 2011-11-23 | 2017-03-16 | Ozstar Therapeutics Pty Ltd | Improved synergistic anti-diabetic compositions |
| CN103159651B (zh) * | 2011-12-14 | 2015-06-17 | 安徽贝克联合制药有限公司 | 磺酰脲胍及其制备方法和用途 |
| WO2015077571A1 (en) | 2013-11-22 | 2015-05-28 | Fractyl Laboratories, Inc. | Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract |
| IL296643B2 (en) | 2012-02-27 | 2025-03-01 | Fractyl Health Inc | Hot ablation systems, devices and methods for tissue treatment |
| WO2013159066A1 (en) | 2012-04-19 | 2013-10-24 | Fractyl Laboratories, Inc. | Tissue expansion devices, system and methods |
| EP3714826A1 (en) | 2012-07-30 | 2020-09-30 | Fractyl Laboratories, Inc. | Electrical energy ablation systems and devices for the treatment of tissue |
| EP2882362B1 (en) | 2012-08-09 | 2024-01-03 | Fractyl Health, Inc. | Ablation systems, devices and methods for the treatment of tissue |
| WO2014055997A1 (en) | 2012-10-05 | 2014-04-10 | Fractyl Laboratories Inc. | Methods, systems and devices for performing multiple treatments on a patient |
| WO2014197632A2 (en) | 2013-06-04 | 2014-12-11 | Fractyl Laboratories, Inc. | Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract |
| US11986235B2 (en) | 2013-09-12 | 2024-05-21 | Fractyl Health, Inc. | Systems, methods and devices for treatment of target tissue |
| US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
| US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
| EP3169260B1 (en) | 2014-07-16 | 2019-09-25 | Fractyl Laboratories, Inc. | System for treating diabetes and related diseases and disorders |
| US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| CN108079000A (zh) * | 2018-02-01 | 2018-05-29 | 湖南博隽生物医药有限公司 | 一种治疗糖尿病的药物组合物及其制备方法 |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| US12350264B2 (en) | 2019-11-22 | 2025-07-08 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder |
| US12403138B2 (en) * | 2019-11-22 | 2025-09-02 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| WO2021146535A1 (en) | 2020-01-15 | 2021-07-22 | Fractyl Laboratories, Inc. | Automated tissue treatment devices, systems, and methods |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009823A1 (en) * | 1994-09-28 | 1996-04-04 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
| EP0749751A2 (en) * | 1995-06-20 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for use in tteatment of diabetes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU706628B2 (en) * | 1995-07-03 | 1999-06-17 | Sankyo Company Limited | Treatment of arteriosclerosis and xanthoma |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
-
1997
- 1997-11-13 US US08/970,057 patent/US5859037A/en not_active Expired - Fee Related
- 1997-12-01 SK SK1118-99A patent/SK111899A3/sk unknown
- 1997-12-01 TR TR1999/02033T patent/TR199902033T2/xx unknown
- 1997-12-01 CA CA002272478A patent/CA2272478A1/en not_active Abandoned
- 1997-12-01 WO PCT/US1997/021996 patent/WO1998036755A1/en not_active Ceased
- 1997-12-01 CZ CZ992892A patent/CZ289299A3/cs unknown
- 1997-12-01 CN CN97181434A patent/CN1244801A/zh active Pending
- 1997-12-01 PL PL97335166A patent/PL335166A1/xx unknown
- 1997-12-01 AU AU55908/98A patent/AU741215B2/en not_active Ceased
- 1997-12-01 EA EA199900725A patent/EA199900725A1/ru unknown
- 1997-12-01 IL IL13002797A patent/IL130027A/xx not_active IP Right Cessation
- 1997-12-01 JP JP53661198A patent/JP2001512478A/ja not_active Abandoned
- 1997-12-01 KR KR1019997007469A patent/KR20000071179A/ko not_active Ceased
- 1997-12-01 BR BR9714505A patent/BR9714505A/pt not_active Application Discontinuation
- 1997-12-01 HU HU0001528A patent/HUP0001528A3/hu unknown
- 1997-12-01 EP EP97952250A patent/EP0957923A1/en not_active Withdrawn
- 1997-12-01 EE EEP199900345A patent/EE9900345A/xx unknown
- 1997-12-01 NZ NZ336002A patent/NZ336002A/en unknown
- 1997-12-30 HN HN1997000167A patent/HN1997000167A/es unknown
-
1998
- 1998-01-22 SV SV1998000010A patent/SV1998000010A/es active IP Right Grant
- 1998-02-17 UY UY24893A patent/UY24893A1/es not_active Application Discontinuation
- 1998-02-18 PE PE1998000113A patent/PE74399A1/es not_active Application Discontinuation
- 1998-02-18 PA PA19988447401A patent/PA8447401A1/es unknown
- 1998-02-18 ZA ZA981343A patent/ZA981343B/xx unknown
- 1998-02-18 AR ARP980100723A patent/AR011829A1/es unknown
- 1998-02-18 GT GT199800037A patent/GT199800037A/es unknown
- 1998-10-16 US US09/173,911 patent/US5972973A/en not_active Expired - Fee Related
-
1999
- 1999-05-27 IS IS5058A patent/IS5058A/is unknown
- 1999-08-18 NO NO993982A patent/NO993982L/no not_active Application Discontinuation
- 1999-08-19 BG BG103671A patent/BG103671A/xx unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009823A1 (en) * | 1994-09-28 | 1996-04-04 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
| EP0749751A2 (en) * | 1995-06-20 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for use in tteatment of diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0957923A1 (en) | 1999-11-24 |
| JP2001512478A (ja) | 2001-08-21 |
| CA2272478A1 (en) | 1998-08-27 |
| AR011829A1 (es) | 2000-09-13 |
| US5859037A (en) | 1999-01-12 |
| BR9714505A (pt) | 2000-03-21 |
| CN1244801A (zh) | 2000-02-16 |
| HN1997000167A (es) | 1999-02-09 |
| EE9900345A (et) | 2000-02-15 |
| PE74399A1 (es) | 1999-08-20 |
| IS5058A (is) | 1999-05-27 |
| BG103671A (en) | 2000-04-28 |
| US5972973A (en) | 1999-10-26 |
| ZA981343B (en) | 1998-11-16 |
| UY24893A1 (es) | 1998-07-10 |
| IL130027A (en) | 2005-09-25 |
| KR20000071179A (ko) | 2000-11-25 |
| HUP0001528A3 (en) | 2000-12-28 |
| SK111899A3 (en) | 2000-09-12 |
| TR199902033T2 (xx) | 2000-02-21 |
| EA199900725A1 (ru) | 2000-04-24 |
| PL335166A1 (en) | 2000-04-10 |
| CZ289299A3 (cs) | 1999-11-17 |
| SV1998000010A (es) | 1999-02-02 |
| AU5590898A (en) | 1998-09-09 |
| NO993982D0 (no) | 1999-08-18 |
| NZ336002A (en) | 2002-03-28 |
| WO1998036755A1 (en) | 1998-08-27 |
| PA8447401A1 (es) | 2001-12-14 |
| IL130027A0 (en) | 2000-02-29 |
| GT199800037A (es) | 1999-08-12 |
| HUP0001528A2 (hu) | 2000-11-28 |
| NO993982L (no) | 1999-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU741215B2 (en) | Sulfonylurea-glitazone synergistic combinations for diabetes | |
| CA2345524C (en) | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide | |
| Culy et al. | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus | |
| Horton et al. | Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes | |
| US6586438B2 (en) | Antidiabetic formulation and method | |
| Poon et al. | Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study | |
| JP2003519621A5 (enExample) | ||
| US20120308511A1 (en) | Co-Therapy for Diabetic Conditions | |
| US6492339B1 (en) | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof | |
| US20050222262A1 (en) | Novel NIDDM regimen | |
| US20130030053A1 (en) | Novel niddm regimen | |
| MXPA99007574A (en) | Sulfonylurea-glitazone synergistic combinations for diabetes | |
| AU8022900B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |